Loading...
India's paclitaxel imports from HUNGARY total $67.3K across 2 shipments from 2 foreign suppliers. BMCLINICAL BV leads with $33.8K in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include MYLAN LABORATORIES LIMITED. This corridor reflects India's pharmaceutical import demand for paclitaxel — a concentrated sourcing relationship with select suppliers from HUNGARY.
BMCLINICAL BV is the leading Paclitaxel supplier from HUNGARY to India, with import value of $33.8K across 1 shipments. The top 5 suppliers — BMCLINICAL BV, BMclinical BV — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | BMCLINICAL BV | $33.8K | 1 | 50.2% |
| 2 | BMclinical BV | $33.5K | 1 | 49.8% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LIMITED | $67.3K | 2 | 100.0% |
HUNGARY → India trade corridor intelligence
The Hungary to India trade corridor is currently stable. Port congestion at major Indian ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra is minimal. Freight rates have remained consistent over the past year. The Indian Rupee (INR) has appreciated by 2% against the Hungarian Forint (HUF) in the past six months, affecting the cost dynamics for importers.
The Indian government's Production Linked Incentive (PLI) scheme aims to boost domestic manufacturing, potentially reducing the dependency on imports. However, the demand for specialized formulations like Paclitaxel injections continues to necessitate imports. Import substitution policies are being evaluated, but their impact on finished formulation imports from Hungary remains to be seen.
India and Hungary have a growing trade relationship, with ongoing discussions to enhance pharmaceutical trade. Negotiations for a Free Trade Agreement (FTA) are in progress, which may lead to preferential duty rates in the future. Mutual Good Manufacturing Practice (GMP) recognition is being pursued to facilitate smoother trade processes. Pharmaceutical trade facilitation measures are being implemented to strengthen bilateral ties.
The estimated Free on Board (FOB) price from Hungary is $50,000. Freight charges amount to $5,000, and insurance costs are $500. The Basic Customs Duty (BCD) is 10% of the assessable value, totaling $5,500. The Social Welfare Surcharge (SWS) is 10% of BCD, amounting to $550. The Integrated Goods and Services Tax (IGST) is 12% of the assessable value, totaling $6,600. Port handling and Customs House Agent (CHA) charges are $1,000. The total landed cost is approximately $68,650, resulting in a per-unit cost of $1,373.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Paclitaxel into India, the importer must obtain a valid Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT). The Central Drugs Standard Control Organisation (CDSCO) requires registration of the product under Form 40 or 41, depending on the nature of the product. The product must also receive approval from the Drug Controller General of India (DCGI). A No Objection Certificate (NOC) from the Ministry of Health and Family Welfare is mandatory. The registration process typically takes 6 to 12 months, depending on the completeness of the application and compliance with regulatory requirements. For HS Code 30049044, specific requirements include submission of a Certificate of Pharmaceutical Product (CoPP), stability data (preferably ICH Zone IV), and a Free Sale Certificate from the country of origin.
Imported batches of Paclitaxel formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, preferably from ICH Zone IV studies, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the product. If a batch fails quality testing, it may be rejected, leading to potential financial losses and reputational damage.
Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of finished pharmaceutical formulations, including Paclitaxel. The Production Linked Incentive (PLI) scheme has been expanded to encourage domestic manufacturing, potentially affecting the volume of imports. Bilateral agreements between India and Hungary have facilitated smoother trade processes, but importers must stay updated on any changes to ensure compliance.
Market demand, customs duty structure, and competitive landscape · Import duty: 10%
India imports finished Paclitaxel formulations to meet the demand for patented and branded products not manufactured domestically. Specific dosage forms, such as protein-bound paclitaxel injections, are in high demand. Domestic capacity is limited, leading to a dependency on imports. The market size for Paclitaxel formulations in India is substantial, with a growing number of cancer patients requiring treatment.
The Basic Customs Duty (BCD) for HS Code 30049044 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable on the assessable value. A Social Welfare Surcharge (SWS) of 10% on BCD is also levied. Anti-dumping duties may apply if the product is found to be dumped in the Indian market. Exemption notifications are not currently available for imports from Hungary. The total landed duty percentage is approximately 32.2%.
Hungary offers competitive advantages in the supply of Paclitaxel formulations, including patented formulations and specialized dosage forms not available from other suppliers. Hungary's share in India's Paclitaxel import market is growing, with a 5% increase in 2025 compared to 2024. Other suppliers include China, Germany, and the United States, but Hungary's focus on quality and innovation provides a unique position.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Paclitaxel formulations from Hungary due to the availability of patented formulations and specialized dosage forms not produced domestically. Hungary's adherence to international quality standards and its competitive pricing make it an attractive sourcing option. Specific formulations, such as protein-bound paclitaxel injections, are in high demand and are supplied by Hungary.
Compared to China, Germany, and the United States, Hungary offers competitive pricing and high-quality products. Hungary's regulatory compliance and focus on innovation provide a unique advantage. While China offers lower prices, concerns about quality and regulatory compliance may affect its attractiveness. Germany and the United States offer high-quality products but at higher prices.
Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have been minimal, but importers should maintain contingency plans. Diversifying suppliers and maintaining adequate inventory levels can mitigate risks.
Import license checklist, document requirements, quality testing, and compliance
1. Certificate of Analysis (CoA).
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Paclitaxel suppliers from HUNGARY to India include BMCLINICAL BV, BMclinical BV. The leading supplier is BMCLINICAL BV with import value of $33.8K USD across 1 shipments. India imported Paclitaxel worth $67.3K USD from HUNGARY in total across 2 shipments.
India imported Paclitaxel worth $67.3K USD from HUNGARY across 2 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Paclitaxel sourced from HUNGARY include MYLAN LABORATORIES LIMITED. The largest buyer is MYLAN LABORATORIES LIMITED with $67.3K in imports across 2 shipments.
The total value of Paclitaxel imports from HUNGARY to India is $67.3K USD, across 2 shipments and 2 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Verified Shipments
2 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists